OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $13.4286.

Several research analysts recently weighed in on the company. B. Riley Financial dropped their target price on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. UBS Group set a $10.00 price target on OptimizeRx in a research note on Wednesday, May 13th. Stephens cut their price objective on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 13th. Finally, Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th.

OptimizeRx Stock Up 0.3%

Shares of OPRX traded up $0.02 during trading hours on Tuesday, hitting $6.37. The company had a trading volume of 103,301 shares, compared to its average volume of 459,931. OptimizeRx has a one year low of $4.54 and a one year high of $22.25. The company’s fifty day moving average price is $5.45 and its two-hundred day moving average price is $7.92. The company has a market capitalization of $119.50 million, a PE ratio of 18.20 and a beta of 1.08. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. As a group, equities analysts forecast that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the 2nd quarter valued at approximately $44,000. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in OptimizeRx during the fourth quarter worth $62,000. Aaron Wealth Advisors LLC purchased a new position in OptimizeRx during the first quarter valued at $66,000. Finally, Hsbc Holdings PLC purchased a new position in OptimizeRx during the first quarter valued at $85,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.